CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has received notification from ...

Currently, only 10% of the drugs that enter Phase I receive marketing approval from the U.S. Food and Drug Administration (FDA), with unmanageable toxicity accounting for approximately 30% of the ...

Repolarization abbreviation with the antiarrhythmic drug mexiletine has been found to normalize the QTc interval and reduce the rate of events in long QT syndrome type 3 (LQT3), but it is only ...

Evaluating new approaches for more efficient and effective target identification Screening of compounds for drug activity and other properties is an important discipline involving chemistry, ...